致敬科学!首款口服抗新冠病毒疗法有望问世,全球“战疫”掀开崭新篇章
今日,医药人的朋友圈被一条重磅消息刷屏:默沙东与Ridgeback Biotherapeutics公司宣布,其一款在研口服抗病毒小分子药物可显著减少因新冠而住院或死亡的风险。基于积极临床结果,独立的数据监察委员会也推荐提前结束临床试验。这款创新疗法有望成为全球抗新冠武器库中的重要一员,为早日终结疫情贡献自己的一份力量。
▲Molnupiravir在临床试验中取得了积极成果(图片来源:Credit - 默沙东)
▲部分位于临床研发阶段的口服抗新冠病毒药物(数据来源:参考资料[2],Evaluate Pharma & clinicaltrials.gov;制图:药明康德内容团队)
来源:药明康德
参考资料:
[1] Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study, Retrieved October 1, 2021, from https://www.businesswire.com/news/home/20211001005189/en/Merck-and-Ridgeback%E2%80%99s-Investigational-Oral-Antiviral-Molnupiravir-Reduced-the-Risk-of-Hospitalization-or-Death-by-Approximately-50-Percent-Compared-to-Placebo-for-Patients-with-Mild-or-Moderate-COVID-19-in-Positive-Interim-Analysis-of-Phase-3-Study
[2] Unexpected win opens the way to an oral Covid antiviral, Retrieved October 1, 2021, from https://www.evaluate.com/vantage/articles/news/trial-results/unexpected-win-opens-way-oral-covid-antiviral
版权声明:部分文章在推送时未能与原作者取得联系。若涉及版权问题,敬请原作者联系我们。联系方式:[email protected]。
阅读原文 关键词
药物
病毒
来源
参考资料
from https
最新评论
推荐文章
作者最新文章
你可能感兴趣的文章
Copyright Disclaimer: The copyright of contents (including texts, images, videos and audios) posted above belong to the User who shared or the third-party website which the User shared from. If you found your copyright have been infringed, please send a DMCA takedown notice to [email protected]. For more detail of the source, please click on the button "Read Original Post" below. For other communications, please send to [email protected].
版权声明:以上内容为用户推荐收藏至CareerEngine平台,其内容(含文字、图片、视频、音频等)及知识版权均属用户或用户转发自的第三方网站,如涉嫌侵权,请通知[email protected]进行信息删除。如需查看信息来源,请点击“查看原文”。如需洽谈其它事宜,请联系[email protected]。
版权声明:以上内容为用户推荐收藏至CareerEngine平台,其内容(含文字、图片、视频、音频等)及知识版权均属用户或用户转发自的第三方网站,如涉嫌侵权,请通知[email protected]进行信息删除。如需查看信息来源,请点击“查看原文”。如需洽谈其它事宜,请联系[email protected]。